High-Flow Nasal Cannula: A Promising Oxygen Therapy for Patients with Severe Bronchial Asthma Complicated with Respiratory Failure
| Autor: | Wuliji Batu, Zhaohui Tong, Shuhong You, Hangyong He, Wan-Ru Geng |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
Adult Male Respiratory rate Article Subject medicine.medical_treatment medicine.disease_cause Severity of Illness Index pCO2 03 medical and health sciences Diseases of the respiratory system 0302 clinical medicine Respiratory Rate Heart Rate Oxygen therapy Heart rate medicine Cannula Humans Asthma Noninvasive Ventilation RC705-779 business.industry Oxygen Inhalation Therapy 030208 emergency & critical care medicine respiratory system medicine.disease respiratory tract diseases Treatment Outcome 030228 respiratory system Respiratory failure Anesthesia Clinical Study Female Blood Gas Analysis business High flow Respiratory Insufficiency Nasal cannula |
| Zdroj: | Canadian Respiratory Journal Canadian Respiratory Journal, Vol 2020 (2020) Canadian respiratory journal, 2020:2301712 |
| ISSN: | 1198-2241 |
| DOI: | 10.1155/2020/2301712 |
| Popis: | Severe bronchial asthma complicated with respiratory failure, a common critical illness in respiratory medicine, may be life-threatening. High-flow nasal cannula (HFNC) is a novel oxygen therapy technique developed in recent years. HFNC was applied in this study for treating adult patients with severe bronchial asthma complicated with respiratory failure. Its efficacy was analyzed comparatively to conventional oxygen therapy (COT). HFNC and COT were randomly performed based on conventional treatment. The HFNC group was similar to COT-treated patients in terms of response rate, with no significant difference in efficacy between the two groups. In patients with bronchial asthma, effectively increased PO2 and reduced PCO2 were observed after treatment in both groups. However, HFNC was more efficient than COT in elevating PO2 in patients with severe bronchial asthma complicated with respiratory failure, while no statistically significant difference in PCO2 reduction was found between the two groups. Heart rate (HR) and respiratory rate (RR) between the two groups on admission (0 h) and at 2, 8, 24, and 48 h after admission were compared. Both indicators significantly decreased with time. No significant differences in HR and RR were found between the groups at 0, 2, and 8 h after admission. However, these indicators were significantly lower in the HFNC group compared with the COT group at 24 and 48 h after admission. HFNC could significantly elevate PO2 and reduce HR and RR. Thus, it is a promising option for patients with severe bronchial asthma complicated with respiratory failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text